Werkgroep Cardiologische centra Nederland

FINEARTS-HF (Follow-up)

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF≥ 40%)
Medicine
finerenone
Population
Heart failure
Phase
III
Starting year
2019